+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Diversity of mechanism-based pharmacodynamic models



Diversity of mechanism-based pharmacodynamic models



Drug Metabolism and Disposition: the Biological Fate of Chemicals 31(5): 510-518



Pharmacodynamics is the study of the time course of pharmacological effects of drugs. The field of pharmacodynamic modeling has made many advances, due in part to the relatively recent development of basic and extended mechanism-based models. The purpose of this article is to describe the classic as well as contemporary approaches, with an emphasis on pertinent equations and salient model features. In addition, current methods of integrating various system complexities into these models are discussed. Future pharmacodynamic models will most likely reflect an assembly of the basic components outlined in this review.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010488248

Download citation: RISBibTeXText

PMID: 12695336

DOI: 10.1124/dmd.31.5.510


Related references

Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus. Antimicrobial Agents and ChemoTherapy 50(9): 2957-2965, 2006

Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans. Antimicrobial Agents and ChemoTherapy 52(3): 937-943, 2008

Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. Journal of Pharmacokinetics and Pharmacodynamics 38(2): 179-204, 2011

Use of physiologically based pharmacokinetic models coupled with pharmacodynamic models to assess the clinical relevance of current bioequivalence criteria for generic drug products containing Ibuprofen. Journal of Pharmaceutical Sciences 103(10): 3263-3275, 2015

The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab. Journal of Pharmaceutical Sciences 95(6): 1258-1268, 2006

Mechanism-based pharmacodynamic modeling. Methods in Molecular Biology 929: 583-600, 2013

Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicology Letters 79(1-3): 35-44, 1995

A mechanism-based pharmacokinetic/pharmacodynamic model for omalizumab. Clinical Pharmacology & Therapeutics 69(2): P87, February, 2001

The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures. Toxicology Letters 82-83: 497-504, 1995

Estimating bioavailability of calcium by pharmacokinetic and pharmacodynamic models II Results of pharmacodynamic consideration. Pharmaceutical Research (New York) 12(9 SUPPL ): S105, 1995

Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharmaceutical Research 22(9): 1432-1437, 2005

Biologically based pharmacodynamic models: tools for toxicological research and risk assessment. Annual Review of Pharmacology and Toxicology 31: 503-523, 1991

Effect of pharmacodynamic baseline changes in linked and indirect pharmacokinetic-pharmacodynamic models. Clinical Pharmacology & Therapeutics 59(2): 155, 1996

Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. Yao Xue Xue Bao 44(4): 406-411, 2010